|
The Measurement of Handicap in Dermatology
Summary of relevant publications by A Y Finlay & Colleagues
ORIGINAL RESEARCH Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol, 1987; l2: 8-ll. Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol, 1989; 14: 194-198. Eun HC, Finlay AY. Measurement of atopic dermatitis disability. Annals of Dermatology, 1990; 2: 9-12. Dooley G, Finlay AY. Personal construct systems of psoriatic patients. Clin Exp Dermatol, 1990; 15: 401-405. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol, 1990; 123: 751-756. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol, 1992; 17: 1-3. Long CC, Funnell CM, Collard R, Finlay AY. What do members of the National Eczema Society really want? Clin Exp Dermatol, 1993; 18: 516-522.
Salek MS, Finlay AY, Luscombe DK, Allen BR,
Berth-Jones J, Camp RDR, Graham-Brown RAC, Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol, 1994; 19: 210-216. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol, 1995; 132: 236-244. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol, 1995; 132: 942-949. Kurwa H, Finlay AY. Dermatology inpatient admission greatly improves life quality. Br J Dermatol, 1995; 133: 575-578 . Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Quality of Life Research, 1996;5: 131-138. Blackford S, Roberts DL, Salek MS, Finlay AY. Basal cell carcinomas cause little handicap. Quality of Life Research, 1996; 5: 191-194. Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporine in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol, 1996; 34: 1016-1021. Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol, 1996; 7: 149-154. Harris A, Burge SM, Dykes PJ, Finlay AY. Handicap in Darier’s disease and Hailey-Hailey disease. Br J Dermatol, 1996; 135: 959-963. Blackford S, Finlay AY, Roberts DL. Quality of life in Behcet’s Syndrome: 335 patients surveyed. Br J Dermatol, 1997; 136: 293. Newton JN, Mallon E, Klassen A, Ryan TJ, Finlay A. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol, 1997; 137: 563-567. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol, 1998; 138: 107-113. Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M, Finlay AY, Soto P, Poncet M, Verschoore M, Clucas A. Evaluation of clinical efficacy and safety of adalpalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol, 1998; 139 (Suppl 52): 26-33. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. BrJ Dermatol, 1999; 140: 672-676.
Harper JI, Ahmed I, Barclay G, Lacour M,
Hoeger P, Cork MJ, Finlay AY et al. Cyclosporin for severe childhood atopic
dermatitis: short course versus continuous therapy. Br J Dermatol,
2000; 142: Ayyalaraju RS, Finlay AY. Inpatient Dermatology: United Kingdom and United States similarities. Chapter in Dermatologic clinics: Inpatient dermatology. Eds: FA Kerdel, RS Kirsner, Dermatologic Clinics 2000; 18(3): 397-404. Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000; 143: 979-982. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infant’s Dermatitis Quality of Life Index. Br J Dermatol, 2001; 144: 104-110. Touw CR, Hakkaart-Van Roisen L, Verboom P, Paul C, Rutten FFH, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144:967-972. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2001; 15: 137-139. Hermansen SE, Helland CA, Finlay AY. Patients’ and doctors’ assessment of skin disease handicap. Clin Exp Dermatology 2002; 27: 249-250. Fivenson D, Arnold R J G, Kaniecki D J, Cohen J L, Frech F, Finlay A Y. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Managed Care Pharmacy 2002; 8 (5): 333-342. Salek M S, Finlay A Y. Quality of Life in patients with severe psoriasis receiving cyclosporin: a multi-centre study. J Applied Therapeutic Research 2003; 4: 3-10. Holme S A, Mann I, Sharpe J L, Dykes P J, Lewis-Jones M S, Finlay A Y. The Childrens’ Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003; 148: 285-290. Loo W-J, Diba V, Chawla M, Finlay A Y. Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003; 148: 279-284. Finlay A Y, Salek M S, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206(4): 307-315. Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kirsner R S, Kerdel F A. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: A comparative study. JAAD 2003; 49: 249-254. Salek M S, Finlay A Y, Lewis J J C, Sumner M I. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral®). Quality of Life Research 2004; 13: 91-95. Szepietowski J, Salomon J, Finlay A Y, Klepacki A, Chodynicka B, Marioneau N, Taieb C, Myon E. Dermatology Life Quality Index: Polish Version. Dermatologia Kliniczna 2004; 6: 63-70. Dreno B, Finlay A Y, Nocera T, Verriere F, Taieb C, Myon E. CADI: Cultural and linguistic validation into French of an acne disability index, Dermatology 2004; 208: 104-108. Lewis V, Finlay A Y. Ten years experience of the Dermatology Life Quality Index (DLQI) J Investig Dermatol Symp Proc 2004; 9(2):169-180. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay A Y. DLQI scores in vitiligo: reliability and validity of the Persian Version. BMC Dermatology 2004; 4: 8. Katugampola R P, Hongbo Y, Finlay A Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. BJD 20005; 152: 1256-1262. Hongbo Y , Thomas C L, Harrison M A, Salek M S, Finlay A Y. Translating the science of quality of life into practice: what do DLQI scores mean? JID 2005; 125: 659-664. David S E, Ahmed Z, Salek M S, Finlay A Y. Does enough quality of life related discussion occur during dermatology outpatient consultations? BJD 2005; 153: 997-1000. Krueger G G, Langley R G, Finlay A Y, Griffiths C E M, Woolley J M, Lalla D, Jahreis A. Patient-reported outcomes of psoriasis improvement with etanercept therapy; results of a randomized phase II trial. BJD 2005; 153: 1192-1199. Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN, Erythropoetic protoporphyria in the UK: Clinical features and effect on quality of life. Br J Dermatol 2006; 155: 374-381. Takahashi N, Suzukamo Y, Natamura M, Miyachi Y, Green J, Ohya Y, Finlay A Y, Fukuhara S. Japanese version of the Dermatology Life Quality Index : Validity and reliability in patients with acne. Health Qual Life Outcomes 2006: 4(1): 46 (e-pub) REVIEWS Finlay AY. Psychological aspects of acne - an overview. Symposium Proceedings "Treating the Acne Patient: The Skin and the Psyche". Barcelona, November 1988. Pennine Press, Cheshire, 1989. Motley RJ, Phillips G, Finlay AY. How much disability is caused by acne? Chapter in "Acne and Related Disorders". Ed Marks R, Plewig G. Martin Dunitz, London, 1989, p141-143. Salek MS, Finlay AY, Khan GK, Luscombe DK. Quality of life measurement in patients with psoriasis. Chapter 48 in "Progress in Clinical Pharmacy". Rational Use of Drugs. Proc of the 18th European Symposium on Clinical Pharmacy, Nijmegen, 1989. Editors Muller NF, Hekster YA. Amsterdam Medical Press, SDU Publishers, The Hague, 1989, p255-259. Finlay AY. Acne : Pathogenesis, disability and treatment. Indian J Dermatol, Venereol Leprol, 1990; 56: 349-353. Motley RJ, Finlay AY. Treat acne early and avoid disability. Mims Magazine, 1991; 18: 15. Finlay AY. The social aspects of skin disease. Update, 1992; 44: 99-106. Finlay AY. Quality of life impairment in atopic dermatitis and psoriasis. Clin Exp Perspectives in Sandimmum Therapy, 1992; 2: 10-11. Finlay AY. Psychological aspects of psoriasis. Sandorama, 1992; 3: 4-8. Finlay AY. Facing up to acne. Occupational Health, 1992; 44: 339-341. Finlay AY. Acne Vulgaris: What are the psychological aspects? Medical Dialogue, 1992; 367: 2-3. Finlay AY. Chair's Summary: Disability from skin disease. Chapter in "Dermatology Progress and Perspectives. Proceedings of the 18th World Congress of Dermatology, New York, June 12-18, 1992". Ed W.H.C. Burgdorf, S.I. Katz. Parthenon Publishing Group, New York, 1993; p1087-1089. Finlay AY. Psychological impact of skin disease. Chapter in "Horizons in Medicine 4", Editors CA Seymour, AM Heagarty. McGraw-Hill, London, 1993, p172-179. Finlay AY. Effect of cyclosporin A on quality of life in psoriasis and eczema. J Dermatol Treat, 1994; 5 (Suppl 1): 513-515. Finlay AY. Quality of Life Survey. Exchange, 1994; 73: 22. Finlay AY. Coping with Psoriasis. BMJ, 1995; 310: 1673 (letter). Elton B, Finlay AY. Psoriasis - it’s not a laughing matter. Dermatology in Practice, 1995, 3 (4), 5-8. Finlay AY. Quality of life issues and economic burden of psoriasis and atopic dermatitis. Clin Drug Invest, 1995; 10, Suppl 1: 1-6. Finlay AY. Quality of life: effects of photodamage. J Dermatol Treat, 1996; 7 (suppl 2): S9-S11. Finlay AY, Ryan TJ. Disability and handicap in dermatology. Internat J Dermatol, 1996; 35: 305-311 . Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol, 1996; 135: 509-515. Finlay A Y. Evaluation of Quality of Life in Dermatology: application to psoriasis. Chapter in Eipdermiology, Causes and prevention of skin disease. Eds J J Grob, R S Stern, R M Mackie, W A Weinstock. Blackwell Science, Oxford 1997. Finlay AY. Dermatological Disability. Medicine, 1997; 25: 8: 6-7. Finlay A Y. Quality of Life Measurement in Dermatology: a practical guide. Br J Dermatol 1997; 136: 305-314 Finlay AY. Dermatology Life Quality Index: initial experience of a simple practical measure. Chapter in: Care management of skin diseases: Life quality and economic impact. Editors: R Rajagopalan, E.F. Sherertz, R.T. Anderson. Marcel Dekker, New York, 1998 p85-94. Finlay AY. Skin Disease Disability: measuring its magnitude. Keio Journal of Medicine, 1998; 47: 131-134. Finlay AY. Quality of life assessments in dermatology. Seminars in Cutaneous Medicine and Surgery, 1998; 17: 291-296. Finlay AY. Quality of life and its measurement. Chapter in “Key Advances in the Effective Management of psoriasis”. Editors: Griffiths C, Barker J. Royal Society of Medicine Press, London, 1999. Finlay A Y. Dermatology patients: what do they really need? Clin Exp Dermatol 2000; 35: 444-450. Finlay A Y. Psoriasis from the patient’s point of view. Arch Dermatol 2001; 137: 352-353. Finlay A Y. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001. 45 (Suppl 1): S64-S66. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay AY, Leyden JJ, Shalita AR, Thiboutot D. Management of Acne. “A report from a Global Alliance to improve outcomes in acne.” J Am Acad Dermatol, 2003: 49 (Suppl. 1): S33-S35. Working Group (including Finlay A Y). Report on the enquiry into the impact of skin diseases on people’s lives. All Party Parliamentary Group on Skin, London, July 2003. Finlay A Y, Burgdorf W H C. Quality of life measurement in atopic dermatitis in ‘Tacrolimus ointment’. Eds: T Ruzicka, S Reitamo. Springer, Berlin 2003, P237-254.
Griffiths C E M,, Dubertret L, Ellis C N,
Finlay A Y, Finzi A F, Ho V C, Johnston A, Katsambas A, Finlay A Y. Quality of Life Indices. Indian J Dermatol Venereol Leprol 2004; 70: 144-149. Cotterill J A, Finlay A Y. General aspects of treatment. Chapter 71 in Rook Textbook of Dermatology, Editors - T Burns, S Breathnach, N Cox, C Griffiths. Blackwells Science, Oxford, 2004. Finlay A Y. Current severe psoriasis and their Rule of Tens. BJD 2005; 152: 861-867. Lewis V J, Finlay A Y. Two Decades Experience of the PDI. Dermatology 2005; 210: 261-268. Katugampola R P, Finlay A Y. Impact of skin diseases on quality of life. Chapter 2.7 in P Fritsch, W Bergdorf (Editors). EDF White Book, Skin Disease in Europe 2nd Edition Berlin 2005, ABW Wissenschaftverlag. Lewis V J, Finlay A Y. A critical review of quality of life scales for psoriasis. Dermatol Clin 2005; 23(4): 707-716. Lewis V J, Ortonne J-P. Patient satisfaction with psoriasis therapies: an update and introduction to biological therapy. J Cutan Med Surg 2005 (May 5: e-pub). Sept –Oct 2004; 8(5): 310-320. Smith S H, Anstey A V, Barker J N W N, Burren A D, Chalmers R J G, Chandler D, Finlay A Y, Griffiths C E M, Jackson K, McHugh N J, McKenna K E, Reynolds N J, Ormerod A D. British Association of Dermatologist Guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497. Finlay A Y. Research methodology in quality of life assessment. Chapter 9 in Psychodermatology, the psychological impact of skin disorders. Editors C Walker, L Papadopoulos. Cambridge University Press, Cambridge 2006. Finlay A Y. The burden of atopic eczema. Chapter 4 in Handbook of Atopic Eczema, 2nd Edition Eds J Ring, B Przybilla, T Ruzicka. Springer-Verlag, Berlin 2006 P31-36. Finlay A Y. Uni- dimensionality of the DLQI – confirmed at last. Acta Dermato-Venereologica 2005; 85: 385. Finlay A Y. The Dermatology Life Quality Index. MIMS Dermatology 2006; 2: 12. Griffiths C E, Katsambas
A, Dijkmans B A, Finlay A Y, Ho V C, Johnston A, Luger T A, Mrowietz U,
Thestrov-Pedersen K. Update on the use of ciclosporin in immune-mediated
dermatoses. ABSTRACTSFinlay AY, Kelly SE. Psoriasis: an Index of Disability. Scot Med J, l985; 30: 266. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Br J Dermatol, 1990; 123 (Suppl. 37): 21-22. Finlay AY, Salek MS, Khan GK, et al. Quality of life improvement in cyclosporin treated atopic dermatitis patients - a double-blind crossover study. (Prize for Best Presentation). Br J Dermatol, 1991; 125 Suppl. 38: 16. Salek MS, Finlay AY, Khan GK, Luscombe DK. Quality of Life in Pharmacotherapy: Reliability and Validity of a General Self-Scored Questionnaire. Pharmaceutisch Weekblad Scientific Edition 92; 14(4) Suppl E: E23. Finlay AY, Khan GK. The Dermatology Life Quality Index: A simple practical measure for routine clinical use. Br J Dermatol, 1993; 129, Suppl 42: 27. Salek MS, Finlay AY. Cyclosporin improves quality of life in psoriasis - Does this matter? Br J Dermatol, 1993; 129, Suppl 42: 32. Herd RM, Tidman MJ, Hunter JAA, Prescott R, Finlay AY, Rutta D. The Lothian atopic dermatitis community study: prevalence, cost and effect on quality of life. Br J Dermatol, 1994; 131, Suppl 44: 24. Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporin in severe childhood atopic dermatitis: a multicentre study. Br J Dermatol, 1994; 131, Suppl 44: 25. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI). Br J Dermatol, 1994; 131, Suppl 44: 26. Herd RM, Tidman MJ, Hunter JAA, Prescott R, Finlay AY. The economic burden of atopic eczema: a community and hospital based assessment. Br J Dermatol, 1994; 131, Suppl 44: 34. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol, 1994; 131, Suppl 44: 37. Kurwa HA, Ashcroft R, Dickinson B, Finlay AY. Dermatology inpatient admission greatly improves life quality. J Dermatol Treat, 1994; 5(4): 248. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S83. Blackford S, Roberts DL, Salek MS, Finlay AY. Basal cell carcinomas and their treatment cause little handicap - the reason for delayed presentation? J Dermatol Treat, 1994; 5(4): 248. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S116. Finlay AY. Quality of life - effects of photodamage. Dermatology, 1995; 190: 262 Salek MS, Finlay AY, Berth-Jones J et al. Effect of cyclosporin on quality of life in severe childhood eczema. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S89-S90. Finlay AY. Evaluation of disability in psoriasis. Les Nouvelles Dermatologiques, 1995; 14 (Suppl 1): 47-48. Lawson V, Lewis-Jones MS, Reid P, Owens RG, Finlay AY. Family impact of childhood atopic eczema. Br J Dermatol, 1995; 133 Suppl 45: 19. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S101. Mallon E, Newton JN, Klassen A, Ryan TJ, Finlay AY. Standard patient-assessed quality of life instruments can be used to measure the benefits of acne treatment. Br J Dermatol, 1995; 133 Suppl 45: 35. Blackford S, Roberts DL, Finlay AY. What is the impact on quality of life of the skin manifestations of Behcet’s syndrome? Br J Dermatol, 1995; 133 Suppl 45: 35-36. Harris AJ, Burge SM, Finlay AY. Quantifying disability in Darier’s Disease. Br J Dermatol, 1995; 133 Suppl 45: 43. Lewis-Jones MS, Lawson V, Hill G, Reid P, Owens G, Finlay AY. Monitoring childhood skin disease handicap. Br J Dermatol 1996; 135, Suppl 47: 52. Finlay AY. The effect of acne on the quality of life. J Invest Dermatol, 1997; 108: 390 Williamson D, Gonzalez M, Finlay AY. Quality of life in patients with hair loss. Br J Dermatol, 1997: 137 Supplement 50, 47. Clark SM, Goulden V, Finlay AY, Cunliffe WJ. The psychological and social impact of acne: a comparison study using three acne disability questionnaires. Br J Dermatol, 1997: 137 Supplement 50, 41. Salek MS, Finlay AY, Sumner MJ. Intermittent short course cyclosporin (neoral) improves quality of life (QOL) in psoriasis. Austral J Dermatol, 1997, 38, Suppl 2, 108. Salek MS, Finlay AY, Sumner MJ. Quality of life impact of long term cyclosporin in severe adult atopic dermatitis - an open multicentre study. Austral J Dermatol, 1997, 38, Suppl 2, 240. Ahmed I, Berth-Jones J, Friedmann P, Graham-Brown R, Cork M, Sowden J, Finlay A, Beard A, Sumner M, Harper JI. Short course versus continuous course therapy of cyclosporin in severe childhood atopic dermatitis. British Journal of Dermatology, 1998; 139 (Suppl 51): 22. Finlay AY, Coles EC, Lewis-Jones MS et al. Quality of life improves after seeing a dermatologist. Br J Dermatol 1998; 139 (Suppl 51): 15. Finlay AY, Lewis-Jones MS, Sharp JL, Dykes PJ. Children’s Dermatology Life Quality Index: cartoon version validation. Br J Dermatol 1998; 139 (Suppl 51): 67-68. Harlow D, Poyner T, Finlay AY, Dykes PJ. High impairment of quality of life of adults with skin diseases in primary care. Br J Dermatol 1998; 139 (Suppl 51): 15. Lewis-Jones MS, Finlay AY, Hill G, Dykes PJ. The impact of atopic dermatitis on children and their families: a community study. 8th International Congress Pediatric Dermatology. Annals de Dermatologie et de Venereologie, 1998; 125 (Suppl 1): S62. Helland CA, Hermansen SE, Finlay AY. Doctor’s perception of patients’ quality of life impairment. J Eur Acad Derm Vener, 1998; 11 (Suppl 2): S257. Grosshans E et al. Adapalene 0.1% gel has a more rapid onset of action than tretinoin 0.025% gel in the treatment of acne vulgaris. J Eur Acad Derm Vener 1998; 11 (Suppl 2), S99. Ayyalaraju RS, Finlay AY, Kirsner RS, Trent JT, Kerdel FA. Dermatology inpatient services: A UK/USA Comparative Study. Br J Dermatol 1999; 141 (Suppl 55): 79-80. Mufleh L, Gonzalez M, Judodihardjo H, Finlay AY. Compliance is high in patients taking oral isotretinoin for acne. British Journal of Dermatology. Br J Dermatol 1999; 141 (Suppl 55): 87. Zaghloul S, Gonzalez M, Judodihardjo H, Finlay AY. The greater the disability, the poorer the topical treatment compliance. Br J Dermatol 1999; 141 (Suppl 55): 48. Lewis-Jones MS, Finlay AY, Dykes PJ. Measurement of the impact of atopic dermatitis on infant’s and their families lives. Br J Dermatol 1999; 141 (Suppl 55): 105-106. Ayyalaraju RS, Finlay AY, Dykes PJ, Trent JT, Kerdel FA, Kirsner RS. Dermatology inpatient services: A UK / USA comparative study. J Invest Dermatol 2000; 114: 886. Lanigan S W, Kwan C K, Dykes P J, Gonzalez M. Quality of life studies in hirsute women receiving ruby laser treatment. Br J Dermatol 2000: 143 (Suppl 57) 42-85. Al-Awadi R, Dykes P J, Gonzalez M, Finlay A Y. Life activity impairment by skin disease. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 54. Aledan M, Gonzalez M, Finlay A Y. Utility measure development for children with skin disease. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 281. Finlay A Y, Corvest M, Lefrancois P, Taieb C. The French version of the psoriasis disability index. JEADV 2001; 15 (Suppl 2): 250. Finlay A Y, Corvest M, Lefrancois P, Taieb C. Psoriasis and current life: preliminary results on 527 subjects. JEADV 2001; 15 (Suppl 2): 244. Dreno B, Finlay AY, Corvest M et al. Follow-up psoriasis-observation and therapy: French initiative. JEADV 2001; 15 (Suppl 2): 238. Finlay AY. Impact of quality of life impairment on compliance. Ann Dermatol Venereol 2002; 129: IS182. Diba VC, Loo W-J, Chawla M, Finlay AY. Dermatology Life Quality Index (DLQI): Validation of an illustrated version. Ann Dermatol Venereol 2002; 129: IS254-253. Lewis-Jones MS, Finlay AY. Measuring quality of life in children. Ann Dermatol Venereol 2002; 129: IS684. Dreno B, Finlay AY, Corvest M, Lefrancois P, Myon E, Taieb C. Psoriasis disability is related to length of history of psoriasis. Ann Dermatol Venereol 2002; 129: IS753. Finlay AY, Corvest TM, Lefrancois P Taieb C. Psoriasis and everyday life: first results on 1,866 subjects. Ann Dermatol Venereol 2002; 129: IS755. Finlay AY, Corvest TM, Lefrancois P Taieb C. The French version of the Psoriasis Disability Index. Ann Dermatol Venereol 2002; 129: IS755. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147 (Suppl 62): 50. Finlay A Y, Corvest M, Lefrancois P, Myon E, Taieb C H. Psoriasis and everyday life: first results on 1866 subjects. JEADV 2002; 16 (Suppl 1): 292. Dreno B, Finlay A Y, Corvest M, Lefrancois P, Myon E, Taieb C. Psoriasis disability is related to the length of history of psoriasis. JEADV 2002; 16 (Suppl 1): 292. Finlay A Y, Myon E, Taieb C. Immoderate exposure to the sun: short-term impact on quality of life. JEADV 2003; 17 (Suppl 3):62. Taieb C, Myon E, Perez N, Finlay A Y. Quality of life and atopic dermatitis: annual assessment in France. JEADV 2003; 17(Suppl 3): 61. A Y Finlay, Del Molino J M, Conesa A, Myon E, Taieb C. Psoriasis and quality of life: Spanish results. JEADV 2003; 17(Suppl 3): 62 Finlay A Y, Dreno B, Nocera T, Verriere F, Myon E, Taieb C. The French version of the Cardiff Acne Disability Index. JEADV 2003; 17(Suppl 3): 62. Finlay A Y. What do quality of life scores really mean? JEADV 2003; 17(Suppl 3): 58. Myon E, Finlay A Y, Dreno B, Corvest M, Lefrancois P Taieb C. A national survey of quality of life in patients with psoriasis. JEADV 2003; 17(Suppl 3): 59. Hongbo Y, Harrison M A, Salek S S, Finlay A Y. Assessing the meaningfulness of Dermatology Life Quality Index (DLQI). JEADV 2003; 17(Suppl 3): 113. Taieb C, Finlay A Y, Lefrancois P, Myon E. Psoriasis: Quality of life according to gender. JEADV 2003; 17(Suppl 3): 375. Taieb C, Finlay A Y, Delmolino J, Conesa A, Myon E. Psoriasis and quality of life: Spanish results. JEADV 2003; 17(Suppl 3): 375. Myon E, Finlay A Y, Lefrancois P, Taieb C. Duration of psoriasis and quality of life. JEADV 2003; 17(Suppl 3): 376. Taieb C, Finlay A Y, Lefrancois P, Myon E. Psoriasis and quality of life SPOT study: results at 3 months. JEADV 2003; 17(Suppl 3): 376. Hongbo Y, Harrison M A, Salek M S, Finlay A Y. What do the Dermatology Life quality Index (DLQI) scores really mean in terms of patients’ overall quality of life. Qual Life Research 2003; 12: 778. Hongbo Y, Thomas C L, Harrison M A, Salek M S, Finlay A Y. Translating the science of quality of life into practice. What do dermatology life quality index scores mean? Br J Dermatol 2004; 151 (Suppl 68): 45-46. Lewis V J, Finlay A Y. Two decades’ experience of the Psoriasis Disability Index. Br J Dermatol 2004; 151 (Suppl 68): 50-51. Katugampola R P, Hongbo Y, Finlay A Y. The relationship between patient-rated quality of life and clinicians’ management decisions in psoriasis – A prospective study. J Invest Dermatol 2004; 123 (2): A70. Salek S, David S, Ahmed Z, Finlay A Y. An evaluation of the relevance of HRQoL discussion in out-patient consultation to the level of impairment as measured by the DLQI. Quality of Life Research 2004; 13: 1522. Taieb C, Finlay A Y, Myon E, Del Molino J. Psoriasis and quality of life: Spanish results. JEADV 2004; 18: 775. Taieb C, Finlay A Y, Myon E. Duration of psoriasis and quality of life. JEADV 2004; 18: 775. Taieb C, Finlay A Y, Myon E. Psoriasis: quality of life according to gender. JEADV 2004; 18: 785. O’Donnell R A, Finlay A Y, Niziol C. The impact of psoriasis on productivity: a survey of psoriasis patients in the UK. JEADV 2004; 18: 788.. Katugampola R P, Hongbo Y, Finlay A Y. Patient centred management decisions for psoriasis. JEADV 2004; 18: 789-790. Taieb C, Finlay A Y, Nocera T, Verriere F, Martin N, Myon E. Impact of hydrotherapy programme on the quality of life of patients suffering from psoriasis. JEADV 2004; 18: 811. Ahmed Z, David S, Salek M S, Finlay A Y. Is there a relationship between the DLQI scores and quality of life related discussions in dermatology out-patient clinic consultations? JEADV 2004; 18 (Suppl 2): 535. Finlay A Y, Myon E, Martin N, Verriere F, Taieb C. Impact of thermal spa on children’s quality of life. JEADV 2004; 18 (Suppl 2): 310. Katugampola R P, Hongbo Y, Finlay A Y. Are clinical management decisions related to the impact of psoriasis on patient-rated quality of life? . JEADV 2004; 18 (Suppl 2): 156. Katugampola R P, Hongbo Y, Finlay A Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. BJD 2005; 152: 1256-1262. Lewis V J, Finlay A Y. Quality of life scale – A critical review. British Epidermo-Epidemiology Society 14th Annual Meeting, Cardiff March 2005. British Journal of Dermatology 2005: 153: 476 Katugampola R P, Thomas C L, Hongbo Y, Salek M S, Finlay A Y. Psoriasis decision taking and the DLQI bands. British Epidermo-Epidemiology Society 14th Annual Meeting, Cardiff March 2005. British Journal of Dermatology 2005: 153: 475-476. Katugampola R, Hongbo Y, Finlay A Y. Patient rated quality of life and clinicians’ management decisions over psoriasis: a prospective study. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 105 (Poster 1314). Thomas C, Hongbo Y, Salek S, Finlay A Y. A Global question approach to aid interpretation of DLQI scores. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 102 (Poster 1301). Taieb C, Finlay A Y, Nguyen C, Myon E. Adults with atopic dermatitis: quality of life impact. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 66 (Poster 700 Taieb C, Finlay A Y, Nguyen C, Myon E. Atopic dermatitis: impact on husbands and wives. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 100 (Poster 203). Finlay A Y, Ortonne J-P, Henninger E. Clinical relevant of improvement in quality of life in psoriasis patients, receiving efalizumab. European Academy of Dermatology & Venereology. 3rd Spring Symposium, Sophia, Bulgaria 19-22 May 2005. Finlay A Y. Decision taking in psoriasis and quality of life. Quality of life in Dermatology Workshop. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM) Davies E, Patel C, Salek M S, Finlay A Y. Quality of life discussions in patients with inflammatory skin disease. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM) Davies S H, Finlay A Y. Psoriasis: Management decision in women. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM) Lewis V J, Finlay A Y. A review of the use of the DLQI in assessing efficacy of the biological therapies in psoriasis. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM) Eghlileb A. Davies E, Finlay A Y. Impact of psoriasis on partner’s and family’s quality of life. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM). Melilli L E, Zhong J, Hoffman R, Finlay A Y. Rapid reduction in disease impact with Adalimumab treatment in patients with moderate to severe chronic plaque psoriasis. 14th Congress of EADV. London, October 2005 JEADV 2005; (CD ROM). Basra M K A, Finlay A Y, Sue-Ho R. The family impact of skin diseases. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM). Salek M S, Varma K, Finlay A Y. Minimal clinical important changes of quality of life scores in dermatology. 14th Congress of EADV. London , October 2005. JEADV 2005; (CD ROM). Salek M S, Patel C, Davies E, Finlay A Y. Are dermatology outpatient clinic consultations patient-centred? 12th Annual Conference of the International Society for Quality of Life Research, San Francisco, CA, USA October 2005. Quality of life Research 2005; 14: 2045. Basra M, Finlay A Y. Family Dermatology Life Quality Index: Conceptualization of a novel dermatology-specific outcome measure for the families of dermatological patients. JAAD 2006; 54(3) Suppl AB118. Davies E, Patel C, Salek S Finlay A Y. Quality of life discussion and patient satisfaction in inflammatory skin disease consultations. JAAD 2006; 54(3) Suppl: AB120. Eghlileb A, Davies E, Finlay A Y. Psoriasis has significant impact on relatives and partners of patients with psoriasis. JAAD 2006; 54(3) Suppl: AB206. Melilli L , Zhong J, Finlay A Y. Rapid improvement in functional limitations of patients with moderate to severe chronic plaque psoriasis treated with Adalimumab. JAAD 2006; 54(3) Suppl AB223 Basra M K A, Su-Ho R, Finlay A Y. Psychometric properties of the Family Dermatology Life Quality Index (FDLQI): A novel dermatology-specific quality of life measure for the families of dermatology patients. Br J Dermatol 2006; 155 (Suppl 1): 7 (p1-9). Katugampola R, Lewis V J, Finlay A Y. A review of the Dermatology Life Quality Index in assessing the efficacy of biological treatments in psoriasis. Br J Dermatol 2006; 155 (Suppl 1): 34 (p21-61) Eglileb A, Davies E E G, Finlay A Y. The secondary impact of psoriasis on the family: The Psoriasis Family Index. Br J Dermatol 2006; 155 (Suppl 1): 31 (p21-61). Basra M K, Finlay A Y. Development and evaluation of the Family Dermatology Life Quality Index. J Investig Dermatol 2006; 126 (Suppl 3):s105.
|